Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 11.
doi: 10.1111/jce.70086. Online ahead of print.

Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE-303 Open-Label Study

James E Ip  1 , Benoit Coutu  2 , John H Ip  3 , Peter A Noseworthy  4 , Maria L Parody  5 , Farhad Rafii  6 , Samuel F Sears  7 , Narendra Singh  8 , Bruce S Stambler  9 , Naeem K Tahirkheli  10 , Juan Agudelo-Uribe  11 , Derek Hu  12 , Silvia Shardonofsky  13 , Muhammad B Sheikh  14 , Anita Holz  14 , David B Bharucha  14 , A John Camm  15
Affiliations

Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE-303 Open-Label Study

James E Ip et al. J Cardiovasc Electrophysiol. .

Abstract

Introduction: Etripamil is a fast-acting intranasally self-administered calcium-channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE-303 is an open-label, single-arm study that evaluated etripamil for multiple, at-home PSVT episodes, without test dose before first use.

Methods: Patients applied an ECG monitor at symptom onset and self-administered etripamil (70 mg) if a vagal maneuver was unsuccessful. ECG monitoring occurred for ≥ 1 h following study drug administration. A repeat 70-mg dose was introduced during the study for symptoms persisting 10 min after the first dose. Safety measures included treatment-emergent adverse events (TEAEs) and ECG arrhythmia-surveillance. Efficacy measures were captured for PSVT termination during treatment of each of the multiple episodes.

Results: 1054 perceived PSVT episodes were etripamil-treated in 503 of 1116 patients enrolled. TEAEs within 24 h were mostly mild or moderate and localized: 30.2% of patients experienced nasal discomfort, nasal congestion (13.9%), rhinorrhea (13.1%), epistaxis (7.4%). TEAE frequencies decreased across multiple PSVT episodes and were similar for single versus repeat doses. For first PSVT episodes, 70.5% of patients converted to sinus rhythm by 60 min post etripamil (median time to conversion = 18.3 min [14.2-25.6]). Conversion in earlier episodes was consistently predictive of conversion in subsequent episodes.

Conclusions: Etripamil nasal spray self-administered in a real-world setting was well tolerated, effective, and had a consistent safety profile as a single- or repeat-dose regimen across multiple PSVT episodes.

Trial registration: ClinicalTrials.gov NCT04072835.

Keywords: NODE‐303; calcium channel blocker; etripamil; nasal spray; paroxysmal supraventricular tachycardia; self‐administered.

PubMed Disclaimer

References

    1. J. Brugada, D. G. Katritsis, E. Arbelo, et al., “2019 ESC Guidelines for the Management of Patients With Supraventricular Tachycardiathe Task Force for the Management of Patients With Supraventricular Tachycardia of the European Society of Cardiology (ESC),” European Heart Journal 41, no. 5 (2020): 655–720.
    1. R. L. Page, J. A. Joglar, M. A. Caldwell, et al., “2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society,” Journal of the American College of Cardiology 68, no. 25 (2016): 2922–2923.
    1. U. Walfridsson, H. Walfridsson, K. Årestedt, and A. Strömberg, “Impact of Radiofrequency Ablation on Health‐Related Quality of Life in Patients With Paroxysmal Supraventricular Tachycardia Compared With a Norm Population One Year After Treatment,” Heart & Lung 40, no. 5 (2011): 405–411.
    1. D. S. Chew, N. C. Sacks, M. R. Emden, et al., “Trends in Health Care Resource Use and Expenditures in Patients With Newly Diagnosed Paroxysmal Supraventricular Tachycardia in the United States,” American Heart Journal 233 (2021): 132–140.
    1. M. Rehorn, N. C. Sacks, M. R. Emden, et al., “Prevalence and Incidence of Patients With Paroxysmal Supraventricular Tachycardia in the United States,” Journal of Cardiovascular Electrophysiology 32, no. 8 (2021): 2199–2206.

Associated data

LinkOut - more resources